Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Medicover - A "charmingly aggressive" CEO

26 augusti 2025

<a id="bm-comp-59995928-8387-4bad-bcbe-0fb9e5b85864" name="bm-comp-59995928-8387-4bad-bcbe-0fb9e5b85864" class="BMCustomAnchor"></a><table><tr><td bm-component-id="59995928-8387-4bad-bcbe-0fb9e5b85864" style="vertical-align: top; width:100.000000%;"><ul><li>Scale and presence underpin growth and margin expansion</li><li>Sharper execution on cross-segment synergies</li><li>Trading at ~13x '25e EV/EBITDA</li></ul></td></tr></table><a id="bm-comp-7f9ec0e2-9956-42ca-ae8e-44ba78678a83" name="bm-comp-7f9ec0e2-9956-42ca-ae8e-44ba78678a83" class="BMCustomAnchor"></a><table><tr><td bm-component-id="7f9ec0e2-9956-42ca-ae8e-44ba78678a83" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3"><strong>Presence matters</strong></h3><p>We hosted Medicover&#8217;s CEO John Stubbington and CFO Anand Patel for lunch earlier today. The discussion centred on how Medicover is positioned to continue delivering strong revenue and earnings growth. At the core of the strategy is the company&#8217;s deep and growing presence across its core markets: Poland, Germany, Romania, and India (illustration from Medicover included further down). The footprint has expanded steadily over the past years, with more members, clinics, hospitals, labs, BDPs, fitness clubs, and medical spaces, which reinforces Medicover&#8217;s ambition to be the go-to provider in each market. Following the lunch, we leave our estimates intact and continue to forecast annual organic sales growth of 15% for '25e-'27e, with adj. EBITDAaL margins improving from 10.9% in '25e to 11.5% in '27e, supported by increased capacity utilisation, maturing units, and a growing share of higher-margin business.</p><h3 class="bm-h3"><strong>Strategic clarity and growing synergy potential</strong></h3><p>Though John Stubbington is new in the CEO role, he&#8217;s been with Medicover since 2010, serving as COO of Healthcare Services. His second appearance at ABGSC showed increased confidence and a clear strategic message: continue in the same direction, but with a sharper focus on group-wide synergies. The integration of M&amp;A teams and shared resources across the two segments signals a shift towards more coordinated execution. Stubbington described himself as &#8220;charmingly aggressive&#8221;, and we see this reflected in the ambition to unlock further value through segment collaboration and smarter capital allocation. While leverage is currently elevated, Medicover has made it clear that the M&amp;A pipeline remains active, with the intention to accelerate once balance sheet flexibility improves.</p><h3 class="bm-h3"><strong>Healthy structural drivers</strong></h3><p>Medicover&#8217;s growth case remains supported by several structural tailwinds: rising healthcare spending, an ageing population, unmet demand in its core markets, and a broad service offering built around a strong brand. The India IPO process appears to be progressing as planned, despite slower growth in Q1'25 delaying it somewhat, with potential updates expected over the next 6&#8211;12 months. On current estimates, Medicover trades at ~13x &#8216;25e EV/EBITDA. Our fair value range of SEK 220-300 corresponds to a &#8216;25e EV/EBITDA of 11x&#8211;14x.</p></td></tr></table><a id="bm-comp-378c43e3-724a-48cf-9c9d-b500662aed70" name="bm-comp-378c43e3-724a-48cf-9c9d-b500662aed70" class="BMCustomAnchor"></a><table><tr><td bm-component-id="378c43e3-724a-48cf-9c9d-b500662aed70" style="vertical-align: top; width:100.000000%;"><table id="bm-img-4fe47247-f421-416d-b141-b39e33ce34d4" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Medicover illustration of local presence in core markets</td></tr><tr><td><img bm-img-encrypt="4fe47247-f421-416d-b141-b39e33ce34d4" bm-img-original-height="796" bm-img-original-width="1682" bm-img-svg="image:image_upload/89987_35841e80-1ef9-421e-a923-32b96b34ba4d.svg" bm-img-width-hint="100%" id="bm-id-4fe47247-f421-416d-b141-b39e33ce34d4" src="https://abgsc.bluematrix.com/images/image_upload/89987_35841e80-1ef9-421e-a923-32b96b34ba4d_732.png" svg="/nas/web/clients/abgsc/images/image_upload/89987_35841e80-1ef9-421e-a923-32b96b34ba4d.svg" width="727" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: Company data</td></tr></table></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-09-08 Infrea - From local roots to larger routes Infrea Analys
2026-09-06 Petrolia Noco - Brage shutdown masked by price an... Petrolia Noco Analys
2026-09-04 Nepa - Marketing measurement on a recurring base Nepa Analys
2026-09-02 Qben Infra - Needs more time to convert growth to... Qben Infra Analys
2026-09-02 Xplora Technologies - A setback, but long-term po... Xplora Tech.. Analys
2026-09-02 Proact - Dell Q2: Storage sales +12% vs cons Proact Analys
2026-08-28 Gentoo Media - Deleveraging focus in H2'26 Gentoo Media Analys
2026-08-27 Lumi Gruppen - Margins strong, but softer intake ... Lumi Gruppen Analys
2026-08-27 Lumi Gruppen - Delivering on H1, H2 looks more ch... Lumi Gruppen Analys
2026-08-26 Inission - Power turnaround progressing well Inission Analys
2026-08-26 Gentoo Media - A bit softer than expected Gentoo Media Analys
2026-08-26 Inission - Inission Power drives beat, demand sti... Inission Analys
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys